An Unprecedented

Approach

to

Tissue

Characterization

BlackLight Surgical has harnessed the principles of Time-Resolved Laser Induced Fluorescence Spectroscopy to create a new biochemical imaging modality for the purpose of characterizing different types of tissues.

An Unprecedented

Approach

to

Tissue

Characterization

BlackLight Surgical has harnessed the principles of Time-Resolved Laser Induced Fluorescence Spectroscopy to create a new biochemical imaging modality for the purpose of characterizing different types of tissues.

Our Process

A Novel Laser-based Technology

BLS technology employs an ultra-fast (<20 picoseconds) ultraviolet laser to excite biochemicals present in tissue. The tissue absorbs the light and, depending on its biochemistry (i.e. the presence of proteins, peptides, and metabolites) emits a pulse of broadband visible light, a phenomenon referred to as Autofluorescence. This light is split into distinct colorbands which are individually captured every 100 ps and amplified by the system. The subsequent patterns of decay over time of the visible light pulse and colorbands are analyzed with the use of machine learning algorithms to distinguish between one tissue type and the next.

Compared to some of the other fluorescence-based techniques, BLS technology is unique in that it does not require any external dyes or drugs thereby avoiding potential complications related to dosage, tolerance, specificity and logistics of adminstering. Furthermore, the regulatory approval process is significantly simplified by non-use of such agents.

Our Process

A Novel
Laser-based
Technology

BLS technology employs an ultra-fast (<20 picoseconds) ultraviolet laser to excite biochemicals present in tissue. The tissue absorbs the light and, depending on its biochemistry (i.e. the presence of proteins, peptides, and metabolites) emits a pulse of broadband visible light, a phenomenon referred to as Autofluorescence. This light is split into distinct colorbands which are individually captured every 100 ps and amplified by the system. The subsequent patterns of decay over time of the visible light pulse and colorbands are analyzed with the use of machine learning algorithms to distinguish between one tissue type and the next.

Compared to some of the other fluorescence-based techniques, BLS technology is unique in that it does not require any external dyes or drugs thereby avoiding potential complications related to dosage, tolerance, specificity and logistics of adminstering. Furthermore, the regulatory approval process is significantly simplified by non-use of such agents.

Our Process

A Novel Laser-based Technology

BLS technology employs an ultra-fast (<20 picoseconds) ultraviolet laser to excite biochemicals present in tissue. The tissue absorbs the light and, depending on its biochemistry (i.e. the presence of proteins, peptides, and metabolites) emits a pulse of broadband visible light, a phenomenon referred to as Autofluorescence. This light is split into distinct colorbands which are individually captured every 100 ps and amplified by the system. The subsequent patterns of decay over time of the visible light pulse and colorbands are analyzed with the use of machine learning algorithms to distinguish between one tissue type and the next.

Compared to some of the other fluorescence-based techniques, BLS technology is unique in that it does not require any external dyes or drugs thereby avoiding potential complications related to dosage, tolerance, specificity and logistics of adminstering. Furthermore, the regulatory approval process is significantly simplified by non-use of such agents.

Our Process

A Novel
Laser-based
Technology

BLS technology employs an ultra-fast (<20 picoseconds) ultraviolet laser to excite biochemicals present in tissue. The tissue absorbs the light and, depending on its biochemistry (i.e. the presence of proteins, peptides, and metabolites) emits a pulse of broadband visible light, a phenomenon referred to as Autofluorescence. This light is split into distinct colorbands which are individually captured every 100 ps and amplified by the system. The subsequent patterns of decay over time of the visible light pulse and colorbands are analyzed with the use of machine learning algorithms to distinguish between one tissue type and the next.

Compared to some of the other fluorescence-based techniques, BLS technology is unique in that it does not require any external dyes or drugs thereby avoiding potential complications related to dosage, tolerance, specificity and logistics of adminstering. Furthermore, the regulatory approval process is significantly simplified by non-use of such agents.

Florescence lifetime represents unique signatures for various tissue types, allowing our technology to identify cancerous tissue intra-operatively and with superior accuracy.
Florescence lifetime represents unique signatures for various tissue types, allowing our technology to identify cancerous tissue intra-operatively and with superior accuracy.

Imaging to new heights

BLS’s implementation of the science has yielded significant customized engineering advances:

High-speed scanning

Allows interrogation of a large tissue specimen (50×60 mm) in about 1 minute.

Ultra-high resolution

Permits identification of tissue spots as small as 125 um.

Next generation connectivity

Enables cloud based data analytics.

Sophisticated optical design

Along with a proprietary sensor delivers unprecedented signal-to-noise (SNR) performance.

Imaging to new heights

BLS’s implementation of the science has yielded significant customized engineering advances:

High-speed scanning

Allows interrogation of a large tissue specimen (50×60 mm) in about 1 minute.

Ultra-high resolution

Permits identification of tissue spots as small as 125 um.

Next generation connectivity

Enables cloud based data analytics.

Sophisticated optical design

Along with a proprietary sensor delivers unprecedented signal-to-noise (SNR) performance.

Key Technology Takeaways

Platform technology – wide
field of application
Non-destructive (allows-in-
vivo imaging) unlike pathology.
Scan only the Surface for
margin assessment.

No external dye or drug required.

Fast, accurate and high
resolution imaging.
Significantly ahead of
competitive approaches.

Key Technology Takeaways

Platform technology – wide
field of application
Non-destructive (allows-in-
vivo imaging) unlike pathology.
Scan only the Surface for
margin assessment.
Accuracy of clinical results in
breast cancer comparable to
pathology (standard of care)
No external dye or drug required.
Fast, accurate and high
resolution imaging.
Significantly ahead of
competitive approaches.
Proprietary AI algorithms
identify tissue signatures with
great precision.

Interested In More

Information

Find out what’s the next chapter in
biochemical imaging and how you can
become a part of it.

Interested In More information?

Find out what’s the next chapter in
biochemical imaging and how you can become a part of it.